Immunobiologics in the treatment of psoriasis

Clinical Immunology

Volumn 123, Issue 2, 2007, Pages 129-138

  Chong, Benjamin F ^a   Wong, Henry K ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Biologics; Inflammation; Psoriasis; Skin disease; T cell; TNF alpha

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P40 ANTIBODY; UNCLASSIFIED DRUG;

ARTHROPATHY; ATOPIC DERMATITIS; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; COMMON COLD SYMPTOM; COUGHING; DEMYELINATING DISEASE; DRUG MECHANISM; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOBIOLOGY; INFECTION; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; LYMPHOMA; MYCOSIS FUNGOIDES; NEUROLOGIC DISEASE; OPTIC NEURITIS; PAPULAR RASH; PARESTHESIA; PATHOGENESIS; PERONEUS NERVE PARALYSIS; PRIORITY JOURNAL; PSORIASIS; RESPIRATORY TRACT DISEASE; SHORT SURVEY; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; TRANSIENT NEUTROPHILLIC DERMATOSIS;

ANTIBODIES, MONOCLONAL; CELL MOVEMENT; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 34247152507     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.01.006     Document Type: Short Survey

References (83)

1. Robert C., and Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med. 341 (1999) 1817-1828
2. Mehlis S.L., and Gordon K.B. The immunology of psoriasis and biologic immunotherapy. J. Am. Acad. Dermatol. 49 (2003) S44-S50
3. Olsen N.J., and Stein C.M. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2167-2179
4. Cather J., and Menter A. Novel therapies for psoriasis. Am. J. Clin. Dermatol. 3 (2002) 159-173
5. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., Billings J.K., Brown M.D., Headington J.T., Cooper K.D., Baadsgaard O., Duell E.A., Amnesley T.M., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256 (1986) 3110-3116
6. Wrone-Smith T., and Nikoloff B.J. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98 (1996) 1878-1887
7. Boyman O., Hefti H.P., Conrad C., Nickoloff B.J., Suter M., and Nestle F.O. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 199 (2004) 731-736
8. Banno T., Gazel A., and Blumenburg M. Effects of tumor necrosis factor-α in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 279 (2004) 32633-32642
9. Barnes P.J., and Karin M. Nuclear factor-κB-a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336 (1997) 1066-1071
10. Brink N., Szamel M., Young A.R., Wittern K.P., and Bergemann J. Comparative quantification of IL-1β, IL-10, IL-10r, TNF-α, and IL-7 mRNA levels in UV-irradiated human skin in vivo. Inflamm. Res. 49 (2000) 290-296
11. Bowcock A.M., and Krueger J.G. Getting under the skin: the immunogenetics of psoriasis. Nat. Rev., Immunol. 5 (2005) 699-711
12. Nickoloff B.J., and Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113 (2004) 1664-1675
13. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
14. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14 (1996) 233-258
15. Watts T.H., and DeBenedette M.A. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11 (1999) 286-293
16. Anderson M.E., and Siahaan T.J. Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 24 (2003) 487-501
17. Sallusto F., Lenig D., Förster R., Lipp M., and Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401 (1999) 708-712
18. Picker L.J., Michie S.A., Rott L.S., and Butcher E.C. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am. J. Pathol. 141 (1992) 1053-1068
19. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
20. H2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7 (1989) 145-173
21. H1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113 (1999) 752-759
22. Sieling P.A., Wang X., Gately M.K., Oliveros J.L., McHugh T., Barnes P.F., Wolf S.F., Golkar L., Yamamura M., Yogi Y., Uyemura K., Rea T.H., and Modlin R.L. IL-12 regulated T helper type 1 cytokine responses in human infectious disease. J. Immunol. 153 (1994) 3639-3647
23. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., Zonin F., Vaisberg E., Churakova T., Liu M., Gorman D., Wagner J., Zurawski S., Liu Y., Abrams J.S., Moore K.W., Rennick D., de Waal-Malefyt R., Hannum C., Bazan J.F., and Kastelein R.A. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000) 715-725
24. + T cells. Immunity 16 (2002) 779-790
25. Kubin M., Kamoun M., and Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180 (1994) 211-222
26. Janeway Jr. C.A., Travers P., Walport M., and Shlomchik M. Immunobiology: the immune system in health and disease. 5th ed. (2001), Garland Publishing, New York 392
27. Rosmarin D., and Strober B.E. The potential of interleukin 12 inhibition in the treatment of psoriasis. J. Drugs Dermatol. 141 (2005) 107-115
28. Shaker O.G., Moustafa W., Essmat S., Abdel-Halim M., and El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clin. Biochem. 39 (2006) 119-125
29. Yawalkar N., Karlen S., Hunger R., Brand C.U., and Braathen L.R. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111 (1998) 1053-1057
30. Economidou J., Barkis J., Demetriou Z., Avgerinou G., Psarra K., Degiannis D., Vareltzidis A., and Katsambas A. Effects of cyclosporine A on immune activation markers in patients with active psoriasis. Dermatology 199 (1999) 144-148
31. Leung D.Y., Gately M., Trumble A., Ferguson-Darnell B., Schlievert P.M., and Picker L.J. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin-12 production. J. Exp. Med. 181 (1995) 747-753
32. Piskin G., Sylva-Steenland R.M., Bos J.D., and Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J. Immunol. 176 (2006) 1908-1915
33. Teunissen M.B., Koomen C.W., de Waal Malefyt R., Wierenga E.A., and Bos J.D. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111 (1998) 645-649
34. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., and Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
35. Finckh A., Simard J.F., Duryea J., Liang M.H., Huang J., Daneel S., Forster A., Gabay C., and Guerne P.A. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum. 54 (2006) 54-59
36. Vaughan T., Osbourn J.K., and Tempest P.R. Human antibodies by design. Nat. Biotechnol. 16 (1998) 535-539
37. Sanders M.E., Makgoba M.W., Sharrow S.O., Stephany D., Springer T.A., Young H.A., and Shaw S. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J. Immunol. 140 (1988) 1401-1407
38. + cells. J. Immunol. 168 (2002) 4462-4471
39. Cooper J.C., Morgan G., Harding S., Subramanyam M., Majeau G.R., Moulder K., and Alexander D.R. Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells. Eur. J. Immunol. 33 (2003) 666-675
40. Gordon K.B., Vaishnaw A.K., O'Gorman J., Haney J., and Menter A. Alefacept Clinical Study Group, treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch. Dermatol. 139 (2003) 1563-1570
41. Fredriksson T., and Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157 (1978) 238-244
42. Feldman S.R., and Krueger G.G. Psoriasis assessment tools in clinical trials. Ann. Rheum. Dis. 64 Suppl. 2 (2005) ii65-ii68
43. Goedkoop A.Y., de Rie M.A., Picavet D.I., Kraan M.C., Dinant H.J., van Kuijk A.W.R., Tak P.P., Bos J.D., and Teunissen M.B.M. Alefacept therapy reduces the effector T cell population in lesional psoriatic epidermis. Arch. Dermatol. Res. 473 (2004) 465-473
44. Chamian F., Lowes M.A., Lin S.L., Lee E., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Cardinale I., Khatcherian A., Novitskaya I., Wittkowski K.M., and Krueger J.G. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2075-2080
45. + T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J. Am. Acad. Dermatol. 49 (2003) 816-825
46. Carlin C.S., Feldman S.R., Krueger J.G., Menter A., and Krueger G.G. A 50% reduction in the psoriasis area and severity index is a clinically significant endpoint in the assessment of psoriasis. J. Am. Acad. Dermatol. 50 (2004) 859-866
47. Lebwohl M., Christophers E., Langley R., Ortonne J.P., Roberts J., and Griffiths C.E. Alefacept Study Group, an international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 139 (2003) 719-727
48. Korman N.J., and Moul D.K. Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use. Semin. Cutan. Med. Surg. 24 (2005) 10-18
49. Krueger G.G. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venerol. 17 Suppl. 2 (2003) 17-24
50. Goffe B., Papp K., Gratton D., Krueger G.G., Darif M., Lee S., Bozic C., Sweetser M.T., and Ticho B. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin. Ther. 27 (2005) 1912-1921
51. Krueger G.G. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol. Clin. 22 (2004) 407-426
52. Jullien D., Prinz J.C., Langley R.G., Caro I., Dummer W., Joshi A., Dedrick R., and Natta P. T-cell modulation for the treatment of chronic plaque psoriasis with Efalizumab (Raptiva): mechanisms of action. Dermatology 208 (2004) 297-306
53. + T cells into lesional skin. Clin. Immunol. 113 (2004) 38-46
54. Lowes M.A., Chamian F., Abello M.V., Fuentes-Duculan J., Lin S., Nussbaum R., Novitskaya I., Carbonaro H., Cardinale I., Kikuchi T., Gilleaudeau P., Sullivan-Whalen M., Wittkowski K.M., Papp K., Garovoy M., Dummer W., Steinman R.M., and Krueger J.G. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 19057-19062
55. Gordon K.B., Papp K.A., Hamilton T.K., Walicke P.A., Dummer W., Li N., Bresnahan B.W., and Menter A. Efalizumab Study Group, Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003) 3073-3080
56. Gottlieb A.B., Gordon K.B., Lebwohl M.G., Caro I., Walicke P.A., Li N., and Leonardi C.L. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. 3 (2004) 614-624
57. Gaylor M.L., and Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J. Drugs Dermatol. 3 (2004) 77-79
58. Orpin S.D., Hafiji J., Goodyear H.M., and Salim A. Ingestion of topical steroid triggering pustular psoriasis?. Br. J. Dermatol. 153 (2005) 680-682
59. Lowes M.A., Turton J.A., Krueger J.G., and Barnetson R.S. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. BMC Dermatol. 5 (2005) 9
60. Peppel K., Crawford D., and Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174 (1991) 1483-1489
61. Lizzul P.F., Aphale A., Malaviya R., Sun Y., Masud S., Dombrovskiy V., and Gottlieb A.B. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J. Invest. Dermatol. 124 (2005) 1275-1283
62. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abella M., Lowes M.A., Chen F., Magliocco M., and Krueger J.G. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175 (2005) 2721-2729
63. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., Goffe B.S., Gaspari A.A., Ling M., Weinstein G.D., Nuyak A., Gordon K.B., and Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139 (2003) 1627-1632
64. Goffe B., and Cather J.C. Etanercept: an overview. J. Am. Acad. Dermatol. 49 (2003) S105-S111
65. Carlson E., and Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 48 (2003) 1165-1166
66. Thomas V.D., Yang F.C., and Kvedar J.C. Biologics in psoriasis: a quick reference guide. J. Am. Acad. Dermatol. 53 (2005) 346-351
67. ten Hove T., van Montfrans C., Peppelenbosch M.P., and van Deventer S.J.H. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
68. Gottlieb A.B., Masud S., Ramamurthi R., Abdulghani A., Romano P., Chaudhari U., Dooley L., Fasanmade A.A., and Wagner C.L. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48 (2003) 68-75
69. Scallon B., Cai A., Solowski N., Rosenberg A., Song X., Shealy D., and Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301 (2002) 418-426
70. Goedkoop A.Y., Kraan M.C., Picavet D.I., de Rie M.A., Teunissen M.B.M., Bos J.D., and Tak P.P. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res. Ther. 6 (2004) R326-R334
71. Krüger-Krasagakis S., Galanopoulos V.K., Giannikaki L., Stefanidou M., and Tosac A.D. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br. J. Dermatol. 154 (2006) 460-466
72. Reich K., Nestle F.O., Papp K., Ortonne J., Evans R., Guzzo C., Shu L., Dooley L.T., and Griffiths C.E.M. EXPRESS study investigators, Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
73. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., Bala M., Marano C.W., and Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51 (2004) 534-542
74. Wallis R.S., Broder M., Wong J., Lee A., and Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin. Infect. Dis. 41 Suppl. 3 (2005) S194-S198
75. Lewis T.G., Tuchinda C., Lim H.W., and Wong H.K. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J. Drugs Dermatol. 5 (2006) 546-548
76. Papp K.A. Potential future therapies for psoriasis. Semin. Cutan. Med. Surg. 24 (2005) 58-63
77. Gordon K.B., Bonish B.K., Patel T., Leonard C.L., and Nickoloff B.J. The tumor necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br. J. Dermatol. 153 (2005) 945-953
78. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., Heffernan M., Miller B., Hamlin R., Lim L., Zhong J., Hoffman R., and Okun M.M. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55 (2006) 598-606
79. Berthelot C.N., George S.J., and Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J. Am. Acad. Dermatol. 53 (2005) S260-S262
80. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., Richert J.R., and Siegel J.N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44 (2001) 2862-2869
81. Patel T., and Gordon K.B. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol. Ther. 17 (2004) 427-431
82. Hong K., Chu A., Ludviksson B.R., Berg E.L., and Ehrhardt R.O. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 15 (1999) 7480-7491
83. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., Everitt D.E., Frederick B., Zhu Y., Graham M.A., Pendley C.E., and Mascelli M.A. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123 (2004) 1037-1044